Biogen Inc. (LON: 0R1B)
London
· Delayed Price · Currency is GBP · Price in USD
142.45
+0.60 (0.42%)
Jan 22, 2025, 7:11 PM BST
Biogen Revenue
Biogen had revenue of $2.47B USD in the quarter ending September 30, 2024, a decrease of -2.55%. This brings the company's revenue in the last twelve months to $9.61B, down -3.86% year-over-year. In the year 2023, Biogen had annual revenue of $9.84B, down -3.32%.
Revenue (ttm)
$9.61B
Revenue Growth
-3.86%
P/S Ratio
n/a
Revenue / Employee
$1.27M
Employees
7,570
Market Cap
16.89B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Biogen News
- 5 days ago - Sage sues Biogen in wake of $469M buyout offer: report - Seeking Alpha
- 7 days ago - Biogen Inc. (BIIB) Appoints New Chief Accounting Officer - GuruFocus
- 7 days ago - Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
- 8 days ago - Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) - Seeking Alpha
- 8 days ago - Biogen CEO sees no burning need for more acquisitions - Reuters
- 8 days ago - Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
- 8 days ago - Biogen stock at lowest level since February 2013 following J.P. Morgan presentation - Seeking Alpha
- 9 days ago - Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review - Seeking Alpha